<DOC>
	<DOC>NCT01617954</DOC>
	<brief_summary>This is a prospective study that will assess the impact of MammaPrint on chemotherapy + endocrine versus endocrine alone treatment decisions in patients with an Oncotype Intermediate Score.</brief_summary>
	<brief_title>PRospective Study Of MammaPrint in Patients With an Intermediate Recurrence Score</brief_title>
	<detailed_description>The frequency of chemotherapy + endocrine versus endocrine alone decisions in Oncotype DX intermediate score patients will be calculated before and after receiving the MammaPrint result.</detailed_description>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Women with histologically proven invasive stage III, node negative, hormone receptor positive, Her2 negative breast cancer, who received an Oncotype DX intermediate score (1830) ≥ 18 years of age at time of consent Written informed consent Insufficient tissue remaining for Mammaprint FFPE Tumor sample shipped to Agendia with ≤ 30% tumor cells or that fails QA or QC criteria Women who have started or completed adjuvant chemotherapy or neoadjuvant chemotherapy</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>